全球披衣菌感染披衣菌和淋病奈瑟菌（CT/NG）检测市场

到 2030 年，全球披衣菌感染衣原体和淋病奈瑟菌 (CT/NG) 检测市场规模将达到 22 亿美元

全球披衣菌感染衣原体和淋病奈瑟菌 (CT/NG) 检测市场规模预计在 2024 年达到 15 亿美元，预计到 2030 年将达到 22 亿美元，2024 年至 2030 年的复合年增长率为 5.7%。 CT/NG 检测耗材是本报告分析的细分市场之一，预计其复合年增长率为 6.9%，到分析期结束时规模将达到 13 亿美元。 CT/NG 检测设备/分析设备细分市场在分析期间的复合年增长率预计为 4.1%。

美国市场规模估计为 4.223 亿美元，而中国市场预计复合年增长率为 9.3%

美国披衣菌感染衣原体和淋病奈瑟菌 (CT/NG) 检测市场规模预计在 2024 年达到 4.223 亿美元。预计到 2030 年，作为世界第二大经济体的中国市场规模将达到 4.435 亿美元，在 2024-2030 年的分析期内，复合年增长率为 9.3%。其他值得关注的区域市场包括日本和加拿大，预计在分析期间内，这两个市场的复合年增长率分别为 2.7% 和 5.7%。在欧洲，预计德国市场的复合年增长率为 3.8%。

全球披衣菌感染衣原体和淋病奈瑟菌 (CT/NG) 检测市场 - 主要趋势和市场驱动因素摘要

为什么 CT/NG 检测是一项重要的公共卫生优先事项？

披衣菌感染衣原体 (CT) 和淋病奈瑟菌 (NG) 是全球最常见的性行为感染(STI) 之一，每年报告数百万新病例。这些细菌感染疾病通常无症状，尤其是在女性中，因此定期筛检对于早期发现和预防骨盆腔发炎 (PID)、不孕症和子宫外孕等长期併发症至关重要。在男性中，未经治疗的筛检可导致附睾炎，并增加感染爱滋病毒的可能性。全球 CT/NG感染疾病的高负担促使各国政府、医疗保健组织和公共卫生机构加强性传染感染筛检项目，尤其是在性活跃的年轻人、孕妇和有多个性伴侣的女性等高风险族群。

随着人们对性健康意识和预防性医疗保健的日益重视，对精准便捷的淋病/鼻咽癌 (CT/NG) 检测解决方案的需求日益增长。传统的培养为基础的诊断方法正被更先进的分子技术所取代，包括核酸增幅检查(NAAT)，这些技术具有更高的灵敏度和特异性。此外，人们对抗生素抗药性淋病日益增长的担忧进一步凸显了早期可靠检测的重要性。然而，诸如资源匮乏地区性传染感染 (STI) 检测机会有限、与性传染感染诊断相关的社会污名以及某些地区缺乏相关认知等挑战，持续阻碍市场的成长。透过资金援助、政策支援和创新检测解决方案的推广，克服这些障碍对于遏制淋病/鼻咽癌 (CT/NG) 感染的传播至关重要。

CT/NG 测试的最新技术进展有哪些？

随着诊断技术的进步，CT/NG 检测格局正在发生显着变化，这些技术提高了准确性、缩短了周转时间并提高了可及性。其中最重要的创新之一是 NAAT 的广泛应用，它可以检测和扩增细菌 DNA 或 RNA，并在短时间内提供灵敏且特异性的结果。基于 NAAT 的检测方法，例如聚合酵素链锁反应(PCR) 和转录媒介增幅(TMA)，由于能够检测尿液、阴道、子宫颈和尿道样本中的低含量细菌，现已成为 CT/NG 检测的黄金标准。此外，同时检测多种性行为感染病原体的多重检测方法也得到了开发，从而提高了诊断效率并实现了更全面的性传播感染筛检。

即时侦测 (POC) 是另一个重大突破，它提供了传统实验室之外的快速、分散式侦测选项。 GeneXpert（Cepheid）和 Abbott ID NOW 等携带式平台可在一小时内诊断出 CT/NG 感染，从而促进当日治疗并降低感染率。此外，自采集套件和居家性传染感染检测服务的进步，使个人能够亲自采集检体并将其送至实验室进行分析，从而提高了可及性。人工智慧 (AI) 和数位健康解决方案与性传染感染诊断的整合也日益增多，人工智慧驱动的诊断工具可辅助数据解读、流行病学追踪和个人化患者管理。随着技术创新的不断推进，CT/NG 检测市场预计将持续扩大，提供更有效率、更便利、更广泛可用的检测方案。

监理政策和市场趋势如何影响 CT/NG 测试产业？

CT/NG 检测产业深受监管政策、公共卫生倡议和不断变化的市场趋势的影响。美国疾病管制与预防中心 (CDC)、世界卫生组织 (WHO) 和欧洲疾病预防控制中心 (ECDC) 等组织的严格指导方针强调了常规 STI筛检的必要性，尤其是对高风险族群。世界各国政府都在增加对国家 STI 控制计画的投资，并扩大社区健康中心、药房和基层医疗诊所的检测机会。此外，保险覆盖范围和报销政策的改善使新兴医疗保健市场的患者更能负担得起 CT/NG 检测。然而，低收入地区医疗保健基础设施和诊断可用性的差异仍然是主要挑战，限制了 STI筛检的广泛应用。

市场趋势表明，人们越来越偏好在家中和直接面向消费者 (DTC) 的性传染感染 (STI) 检测，这得益于这些服务提供的便利性、隐私和可近性。 Everlywell、LetsGetChecked 和 myLAB Box 等公司已推出检体检测套组，让用户在线上谨慎采集样本并取得实验室检验结果。此外，远端医疗与性传染感染诊断的整合实现了远距咨询和处方服务，促进了及时治疗并减轻了医疗机构的负担。数位健康平台的兴起也在简化 CT/NG 检测工作流程方面发挥了关键作用，实现了电子健康记录(EMR) 整合、结果自动通知和数据主导的性传播感染监测。随着公众对性传染感染 (STI) 认识的不断提高，对快速、易用且经济高效的 CT/NG 检测解决方案的需求预计将扩大，并影响性传染感染诊断的未来。

推动 CT/NG 测试市场成长的因素有哪些？

性传染感染疾病/鼻咽癌 (CT/NG) 检测市场的成长受到多种因素的推动，包括分子诊断技术的进步、性传染感染 (STI) 盛行率的上升以及分散式和数位化医疗解决方案的扩展。性传染病/鼻咽癌 (CT/NG) 的盛行率上升，尤其是在年轻人群体中，推动了对定期筛检和早期检测的需求。包括即时PCR和自动化高通量系统在内的创新分子检测法的不断发展，提高了诊断的准确性和效率，使性传播感染 (STI) 检测更加普及。此外，自采集和家用检测套组的普及套件了筛检服务的可近性，解决了获得医疗保健的耻辱感和障碍。

扩大终端应用也是主要的成长动力，检测服务越来越多地被整合到初级保健机构、性健康诊所和线上健康平台。行动医疗(行动医疗) 应用和远端医疗服务的扩展进一步推动了对数位 STI 诊断的需求，使远距咨询、检测订购和治疗访问成为可能。此外，对淋病新型生物标记和抗菌素抗药性 (AMR) 检测的探索为更全面的诊断解决方案铺平了道路，这些解决方案不仅可以检测感染，还可以指南标靶治疗。诊断公司、公共卫生机构和研究机构之间日益加强的合作正在加速产品创新和市场渗透。随着宣传宣传活动和政府主导的STI 预防计划的不断扩大，CT/NG 检测市场预计将透过提供更易于存取、更有效率和以患者为中心的诊断解决方案实现持续成长。

部分

产品类型（CT/NG 测试耗材、CT/NG 测试设备/分析仪）、测试类型（实验室测试、就地检验）、技术（聚合酵素链锁反应技术、恒温核酸增幅技术、免疫诊断技术、其他技术）、最终用户（医院/诊所最终用户、诊断实验室最终用户、居家照护最终用户、其他最终用户）

受访公司范例

• Abbott Laboratories
• Becton, Dickinson and Company
• bioMerieux
• Bio-Rad Laboratories
• Cepheid
• DiaSorin
• GenMark Diagnostics
• Grifols
• Hologic, Inc.
• LabCorp
• Luminex Corporation
• Meridian Bioscience
• OraSure Technologies
• PerkinElmer
• Qiagen
• Quest Diagnostics
• Quidel Corporation
• Roche Diagnostics
• Siemens Healthineers
• Thermo Fisher Scientific

人工智慧集成

全球产业分析师正在利用可操作的专家内容和人工智慧工具改变市场和竞争情报。

Global 特定产业SLM 的典型规范，而是建立了一个从全球专家收集的内容库，其中包括视讯录影、部落格、搜寻引擎研究以及大量的公司、产品/服务和市场数据。

关税影响係数

全球产业分析师根据公司总部所在国家、製造地、进出口状况（成品和原始OEM）预测其竞争态势的变化。这种复杂且多面向的市场动态预计将以多种方式影响竞争对手，包括销货成本成本 (COGS) 上升、盈利下降、供应链重组以及其他微观和宏观市场动态。

目录

第一章调查方法

第二章执行摘要

• 市场概览
• 主要企业
• 市场趋势和驱动因素
• 全球市场展望

第三章市场分析

• 美国
• 加拿大
• 日本
• 中国
• 欧洲
• 法国
• 德国
• 义大利
• 英国
• 西班牙
• 俄罗斯
• 其他欧洲国家
• 亚太地区
• 澳洲
• 印度
• 韩国
• 其他亚太地区
• 拉丁美洲
• 阿根廷
• 巴西
• 墨西哥
• 其他拉丁美洲
• 中东
• 伊朗
• 以色列
• 沙乌地阿拉伯
• 阿拉伯聯合大公国
• 其他中东地区
• 非洲

第四章 比赛

Global Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing Market to Reach US$2.2 Billion by 2030

The global market for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing estimated at US$1.5 Billion in the year 2024, is expected to reach US$2.2 Billion by 2030, growing at a CAGR of 5.7% over the analysis period 2024-2030. CT / NG Testing Consumables, one of the segments analyzed in the report, is expected to record a 6.9% CAGR and reach US$1.3 Billion by the end of the analysis period. Growth in the CT / NG Testing Instruments / Analyzers segment is estimated at 4.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$422.3 Million While China is Forecast to Grow at 9.3% CAGR

The Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing market in the U.S. is estimated at US$422.3 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$443.5 Million by the year 2030 trailing a CAGR of 9.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.7% and 5.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.8% CAGR.

Global Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing Market - Key Trends & Growth Drivers Summarized

Why Is CT/NG Testing Becoming a Critical Public Health Priority?

Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) are among the most prevalent sexually transmitted infections (STIs) worldwide, with millions of new cases reported annually. These bacterial infections often present asymptomatically, particularly in women, making routine screening essential for early detection and prevention of long-term complications such as pelvic inflammatory disease (PID), infertility, and ectopic pregnancy. In men, untreated infections can lead to epididymitis and increased susceptibility to HIV. The global burden of CT/NG infections has prompted governments, healthcare organizations, and public health agencies to strengthen STI screening programs, particularly among high-risk populations such as sexually active young adults, pregnant women, and individuals with multiple sexual partners.

The increasing emphasis on sexual health awareness and preventive healthcare has driven demand for accurate and accessible CT/NG testing solutions. Traditional culture-based diagnostic methods have largely been replaced by more advanced molecular techniques, including nucleic acid amplification tests (NAATs), which offer superior sensitivity and specificity. Additionally, growing concerns about antibiotic-resistant Neisseria gonorrhoeae strains have further highlighted the importance of early and reliable detection. However, challenges such as limited access to STI testing in low-resource settings, social stigma associated with STI diagnosis, and lack of awareness in certain regions continue to hinder market growth. Addressing these barriers through increased funding, policy support, and innovative testing solutions is crucial for controlling the spread of CT/NG infections.

What Are the Latest Technological Advancements in CT/NG Testing?

The CT/NG testing landscape has evolved significantly with advancements in diagnostic technologies that enhance accuracy, reduce turnaround times, and improve accessibility. One of the most significant innovations is the widespread adoption of NAATs, which detect and amplify bacterial DNA or RNA, providing highly sensitive and specific results in a short time. NAAT-based assays, such as polymerase chain reaction (PCR) and transcription-mediated amplification (TMA), are now the gold standard for CT/NG testing due to their ability to detect low bacterial loads in urine, vaginal, cervical, and urethral samples. Furthermore, multiplex assays have been developed to simultaneously detect multiple sexually transmitted pathogens, improving diagnostic efficiency and enabling more comprehensive STI screening.

Point-of-care (POC) testing is another major breakthrough, offering rapid and decentralized testing options outside traditional laboratory settings. Portable molecular platforms, such as GeneXpert (Cepheid) and Abbott ID NOW, have made it possible to diagnose CT/NG infections in under an hour, facilitating same-day treatment and reducing transmission rates. Additionally, advancements in self-collection kits and at-home STI testing services have increased accessibility, allowing individuals to collect samples privately and send them to laboratories for analysis. The integration of artificial intelligence (AI) and digital health solutions into STI diagnostics is also emerging, with AI-powered diagnostic tools assisting in data interpretation, epidemiological tracking, and personalized patient management. As technological innovation continues, the CT/NG testing market is expected to expand, offering more efficient, user-friendly, and widely accessible testing options.

How Are Regulatory Policies and Market Trends Shaping the CT/NG Testing Industry?

The CT/NG testing industry is heavily influenced by regulatory policies, public health initiatives, and evolving market trends. Stringent guidelines from organizations such as the Centers for Disease Control and Prevention (CDC), the World Health Organization (WHO), and the European Centre for Disease Prevention and Control (ECDC) emphasize the need for routine STI screening, particularly among high-risk groups. Governments worldwide are increasing investments in national STI control programs, expanding access to testing in community health centers, pharmacies, and primary care clinics. In addition, insurance coverage and reimbursement policies are improving, making CT/NG testing more affordable for patients in developed healthcare markets. However, disparities in healthcare infrastructure and diagnostic availability in low-income regions remain a significant challenge, limiting widespread STI screening.

Market trends indicate a growing preference for at-home and direct-to-consumer (DTC) STI testing, driven by the convenience, privacy, and accessibility these services provide. Companies such as Everlywell, LetsGetChecked, and myLAB Box have introduced self-testing kits that allow users to collect samples discreetly and receive lab-verified results online. Additionally, the integration of telemedicine with STI diagnostics is enabling remote consultations and prescription services, facilitating timely treatment and reducing the burden on healthcare facilities. The rise of digital health platforms is also playing a crucial role in streamlining CT/NG testing workflows, enabling electronic medical records (EMRs) integration, automated result notifications, and data-driven STI surveillance. As public awareness of STIs continues to rise, the demand for rapid, user-friendly, and cost-effective CT/NG testing solutions is expected to grow, influencing the future of STI diagnostics.

What Is Driving the Growth of the CT/NG Testing Market?

The growth in the CT/NG testing market is driven by several factors, including advancements in molecular diagnostics, increasing STI prevalence, and the expansion of decentralized and digital healthcare solutions. The rising incidence of CT/NG infections, particularly among young adults, has led to greater demand for routine screening and early detection. The continuous development of innovative molecular assays, including real-time PCR and automated high-throughput systems, has improved diagnostic accuracy and efficiency, making STI testing more widely available. Additionally, the adoption of self-collection and at-home testing kits has expanded access to screening services, addressing barriers related to stigma and healthcare accessibility.

End-use expansion is another major growth driver, with testing services being increasingly integrated into primary care settings, sexual health clinics, and online health platforms. The expansion of mobile health (mHealth) applications and telehealth services is further supporting the demand for digital STI diagnostics, enabling remote consultation, test ordering, and treatment access. Additionally, research into novel biomarkers and antimicrobial resistance (AMR) testing for Neisseria gonorrhoeae is paving the way for more comprehensive diagnostic solutions that not only detect infections but also guide targeted therapy. The increasing collaboration between diagnostic companies, public health agencies, and research institutions is accelerating product innovation and market penetration. As awareness campaigns and government-led STI prevention programs continue to expand, the CT/NG testing market is expected to experience sustained growth, offering more accessible, efficient, and patient-centric diagnostic solutions.

SCOPE OF STUDY:

The report analyzes the Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (CT/NG Testing Consumables, CT/NG Testing Instruments/Analyzers); Test Type (Laboratory Testing, Point-of-Care Testing); Technology (Polymerase Chain Reaction Technology, Isothermal Nucleic Acid Amplification Technology, Immunodiagnostics Technology, Other Technologies); End-Use (Hospitals and Clinics End-Use, Diagnostic Laboratories End-Use, Home Care Settings End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

• Abbott Laboratories
• Becton, Dickinson and Company
• bioMerieux
• Bio-Rad Laboratories
• Cepheid
• DiaSorin
• GenMark Diagnostics
• Grifols
• Hologic, Inc.
• LabCorp
• Luminex Corporation
• Meridian Bioscience
• OraSure Technologies
• PerkinElmer
• Qiagen
• Quest Diagnostics
• Quidel Corporation
• Roche Diagnostics
• Siemens Healthineers
• Thermo Fisher Scientific

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Tariff Impact on Global Supply Chain Patterns
  • Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Prevalence of STIs Globally Fuels Demand for Early and Accurate CT/NG Diagnostic Testing
  • Increased Government Screening Programs and Public Health Campaigns Drive Testing Volumes
  • Advancements in NAAT (Nucleic Acid Amplification Test) Technology Improve Diagnostic Accuracy and Sensitivity
  • OEM Expansion Into Point-of-Care and Self-Testing Kits Supports Decentralized Testing Models
  • Integration of CT/NG Testing Into Routine Womens Health Panels Enhances Adoption in Clinical Settings
  • Regulatory Approvals for Dual or Multiplex Panels Improve Efficiency in STI Screening Protocols
  • Rise of Asymptomatic Infections and Re-Infections Highlights Need for Routine, Repeat Testing
  • Digital Sexual Health Platforms and Telemedicine Integration Increase Accessibility of At-Home CT/NG Testing
  • OEM Development of Rapid Test Platforms Supports Use in Urgent Care and Low-Resource Clinics
  • Inclusion of Male and Extra-Genital Testing Expands Population Coverage and Accuracy
  • Global Health Funding and NGO Initiatives Improve Access to Testing in High-Risk Populations
  • Growing Awareness Among Young Adults and Adolescents Boosts Demand for Confidential Testing Options
  • Shift Toward Preemptive STI Screening in IVF, Prenatal, and Pre-Surgical Workups Drives Test Uptake
  • OEM Partnerships With Public Health Labs and Universities Accelerate Test Kit Distribution
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for CT / NG Testing Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for CT / NG Testing Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for CT / NG Testing Consumables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for CT / NG Testing Instruments / Analyzers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for CT / NG Testing Instruments / Analyzers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for CT / NG Testing Instruments / Analyzers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Diagnostic Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Diagnostic Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Diagnostic Laboratories End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Home Care Settings End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Home Care Settings End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Home Care Settings End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Hospitals & Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Laboratory Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Laboratory Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Laboratory Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Point-of-Care Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Point-of-Care Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Point-of-Care Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Polymerase Chain Reaction Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Polymerase Chain Reaction Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Polymerase Chain Reaction Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Isothermal Nucleic Acid Amplification Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Isothermal Nucleic Acid Amplification Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Isothermal Nucleic Acid Amplification Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Immunodiagnostics Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Immunodiagnostics Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Immunodiagnostics Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 40: World 15-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 41: USA Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Product Type - CT / NG Testing Consumables and CT / NG Testing Instruments / Analyzers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Product Type - CT / NG Testing Consumables and CT / NG Testing Instruments / Analyzers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 43: USA 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Product Type - Percentage Breakdown of Value Sales for CT / NG Testing Consumables and CT / NG Testing Instruments / Analyzers for the Years 2015, 2025 & 2030
  • TABLE 44: USA Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by End-Use - Diagnostic Laboratories End-Use, Home Care Settings End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 45: USA Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by End-Use - Diagnostic Laboratories End-Use, Home Care Settings End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 46: USA 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Home Care Settings End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2015, 2025 & 2030
  • TABLE 47: USA Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Test Type - Laboratory Testing and Point-of-Care Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 48: USA Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Test Type - Laboratory Testing and Point-of-Care Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 49: USA 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Test Type - Percentage Breakdown of Value Sales for Laboratory Testing and Point-of-Care Testing for the Years 2015, 2025 & 2030
  • TABLE 50: USA Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Technology - Polymerase Chain Reaction Technology, Isothermal Nucleic Acid Amplification Technology, Immunodiagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 51: USA Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Technology - Polymerase Chain Reaction Technology, Isothermal Nucleic Acid Amplification Technology, Immunodiagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 52: USA 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction Technology, Isothermal Nucleic Acid Amplification Technology, Immunodiagnostics Technology and Other Technologies for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 53: Canada Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Product Type - CT / NG Testing Consumables and CT / NG Testing Instruments / Analyzers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Canada Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Product Type - CT / NG Testing Consumables and CT / NG Testing Instruments / Analyzers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 55: Canada 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Product Type - Percentage Breakdown of Value Sales for CT / NG Testing Consumables and CT / NG Testing Instruments / Analyzers for the Years 2015, 2025 & 2030
  • TABLE 56: Canada Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by End-Use - Diagnostic Laboratories End-Use, Home Care Settings End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Canada Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by End-Use - Diagnostic Laboratories End-Use, Home Care Settings End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 58: Canada 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Home Care Settings End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2015, 2025 & 2030
  • TABLE 59: Canada Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Test Type - Laboratory Testing and Point-of-Care Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Canada Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Test Type - Laboratory Testing and Point-of-Care Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 61: Canada 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Test Type - Percentage Breakdown of Value Sales for Laboratory Testing and Point-of-Care Testing for the Years 2015, 2025 & 2030
  • TABLE 62: Canada Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Technology - Polymerase Chain Reaction Technology, Isothermal Nucleic Acid Amplification Technology, Immunodiagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Canada Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Technology - Polymerase Chain Reaction Technology, Isothermal Nucleic Acid Amplification Technology, Immunodiagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 64: Canada 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction Technology, Isothermal Nucleic Acid Amplification Technology, Immunodiagnostics Technology and Other Technologies for the Years 2015, 2025 & 2030
• JAPAN
  • Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 65: Japan Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Product Type - CT / NG Testing Consumables and CT / NG Testing Instruments / Analyzers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Japan Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Product Type - CT / NG Testing Consumables and CT / NG Testing Instruments / Analyzers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 67: Japan 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Product Type - Percentage Breakdown of Value Sales for CT / NG Testing Consumables and CT / NG Testing Instruments / Analyzers for the Years 2015, 2025 & 2030
  • TABLE 68: Japan Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by End-Use - Diagnostic Laboratories End-Use, Home Care Settings End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Japan Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by End-Use - Diagnostic Laboratories End-Use, Home Care Settings End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 70: Japan 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Home Care Settings End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2015, 2025 & 2030
  • TABLE 71: Japan Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Test Type - Laboratory Testing and Point-of-Care Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Japan Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Test Type - Laboratory Testing and Point-of-Care Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 73: Japan 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Test Type - Percentage Breakdown of Value Sales for Laboratory Testing and Point-of-Care Testing for the Years 2015, 2025 & 2030
  • TABLE 74: Japan Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Technology - Polymerase Chain Reaction Technology, Isothermal Nucleic Acid Amplification Technology, Immunodiagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Japan Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Technology - Polymerase Chain Reaction Technology, Isothermal Nucleic Acid Amplification Technology, Immunodiagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 76: Japan 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction Technology, Isothermal Nucleic Acid Amplification Technology, Immunodiagnostics Technology and Other Technologies for the Years 2015, 2025 & 2030
• CHINA
  • Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 77: China Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Product Type - CT / NG Testing Consumables and CT / NG Testing Instruments / Analyzers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 78: China Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Product Type - CT / NG Testing Consumables and CT / NG Testing Instruments / Analyzers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 79: China 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Product Type - Percentage Breakdown of Value Sales for CT / NG Testing Consumables and CT / NG Testing Instruments / Analyzers for the Years 2015, 2025 & 2030
  • TABLE 80: China Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by End-Use - Diagnostic Laboratories End-Use, Home Care Settings End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 81: China Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by End-Use - Diagnostic Laboratories End-Use, Home Care Settings End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 82: China 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Home Care Settings End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2015, 2025 & 2030
  • TABLE 83: China Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Test Type - Laboratory Testing and Point-of-Care Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 84: China Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Test Type - Laboratory Testing and Point-of-Care Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 85: China 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Test Type - Percentage Breakdown of Value Sales for Laboratory Testing and Point-of-Care Testing for the Years 2015, 2025 & 2030
  • TABLE 86: China Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Technology - Polymerase Chain Reaction Technology, Isothermal Nucleic Acid Amplification Technology, Immunodiagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 87: China Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Technology - Polymerase Chain Reaction Technology, Isothermal Nucleic Acid Amplification Technology, Immunodiagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 88: China 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction Technology, Isothermal Nucleic Acid Amplification Technology, Immunodiagnostics Technology and Other Technologies for the Years 2015, 2025 & 2030
• EUROPE
  • Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 89: Europe Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 90: Europe Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 91: Europe 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 92: Europe Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Product Type - CT / NG Testing Consumables and CT / NG Testing Instruments / Analyzers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Europe Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Product Type - CT / NG Testing Consumables and CT / NG Testing Instruments / Analyzers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 94: Europe 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Product Type - Percentage Breakdown of Value Sales for CT / NG Testing Consumables and CT / NG Testing Instruments / Analyzers for the Years 2015, 2025 & 2030
  • TABLE 95: Europe Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by End-Use - Diagnostic Laboratories End-Use, Home Care Settings End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Europe Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by End-Use - Diagnostic Laboratories End-Use, Home Care Settings End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 97: Europe 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Home Care Settings End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2015, 2025 & 2030
  • TABLE 98: Europe Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Test Type - Laboratory Testing and Point-of-Care Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Europe Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Test Type - Laboratory Testing and Point-of-Care Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 100: Europe 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Test Type - Percentage Breakdown of Value Sales for Laboratory Testing and Point-of-Care Testing for the Years 2015, 2025 & 2030
  • TABLE 101: Europe Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Technology - Polymerase Chain Reaction Technology, Isothermal Nucleic Acid Amplification Technology, Immunodiagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Europe Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Technology - Polymerase Chain Reaction Technology, Isothermal Nucleic Acid Amplification Technology, Immunodiagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 103: Europe 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction Technology, Isothermal Nucleic Acid Amplification Technology, Immunodiagnostics Technology and Other Technologies for the Years 2015, 2025 & 2030
• FRANCE
  • Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 104: France Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Product Type - CT / NG Testing Consumables and CT / NG Testing Instruments / Analyzers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 105: France Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Product Type - CT / NG Testing Consumables and CT / NG Testing Instruments / Analyzers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 106: France 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Product Type - Percentage Breakdown of Value Sales for CT / NG Testing Consumables and CT / NG Testing Instruments / Analyzers for the Years 2015, 2025 & 2030
  • TABLE 107: France Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by End-Use - Diagnostic Laboratories End-Use, Home Care Settings End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 108: France Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by End-Use - Diagnostic Laboratories End-Use, Home Care Settings End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 109: France 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Home Care Settings End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2015, 2025 & 2030
  • TABLE 110: France Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Test Type - Laboratory Testing and Point-of-Care Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 111: France Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Test Type - Laboratory Testing and Point-of-Care Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 112: France 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Test Type - Percentage Breakdown of Value Sales for Laboratory Testing and Point-of-Care Testing for the Years 2015, 2025 & 2030
  • TABLE 113: France Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Technology - Polymerase Chain Reaction Technology, Isothermal Nucleic Acid Amplification Technology, Immunodiagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 114: France Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Technology - Polymerase Chain Reaction Technology, Isothermal Nucleic Acid Amplification Technology, Immunodiagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 115: France 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction Technology, Isothermal Nucleic Acid Amplification Technology, Immunodiagnostics Technology and Other Technologies for the Years 2015, 2025 & 2030
• GERMANY
  • Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 116: Germany Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Product Type - CT / NG Testing Consumables and CT / NG Testing Instruments / Analyzers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Germany Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Product Type - CT / NG Testing Consumables and CT / NG Testing Instruments / Analyzers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 118: Germany 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Product Type - Percentage Breakdown of Value Sales for CT / NG Testing Consumables and CT / NG Testing Instruments / Analyzers for the Years 2015, 2025 & 2030
  • TABLE 119: Germany Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by End-Use - Diagnostic Laboratories End-Use, Home Care Settings End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Germany Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by End-Use - Diagnostic Laboratories End-Use, Home Care Settings End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 121: Germany 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Home Care Settings End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2015, 2025 & 2030
  • TABLE 122: Germany Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Test Type - Laboratory Testing and Point-of-Care Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Germany Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Test Type - Laboratory Testing and Point-of-Care Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 124: Germany 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Test Type - Percentage Breakdown of Value Sales for Laboratory Testing and Point-of-Care Testing for the Years 2015, 2025 & 2030
  • TABLE 125: Germany Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Technology - Polymerase Chain Reaction Technology, Isothermal Nucleic Acid Amplification Technology, Immunodiagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Germany Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Technology - Polymerase Chain Reaction Technology, Isothermal Nucleic Acid Amplification Technology, Immunodiagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 127: Germany 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction Technology, Isothermal Nucleic Acid Amplification Technology, Immunodiagnostics Technology and Other Technologies for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 128: Italy Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Product Type - CT / NG Testing Consumables and CT / NG Testing Instruments / Analyzers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Italy Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Product Type - CT / NG Testing Consumables and CT / NG Testing Instruments / Analyzers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 130: Italy 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Product Type - Percentage Breakdown of Value Sales for CT / NG Testing Consumables and CT / NG Testing Instruments / Analyzers for the Years 2015, 2025 & 2030
  • TABLE 131: Italy Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by End-Use - Diagnostic Laboratories End-Use, Home Care Settings End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Italy Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by End-Use - Diagnostic Laboratories End-Use, Home Care Settings End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 133: Italy 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Home Care Settings End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2015, 2025 & 2030
  • TABLE 134: Italy Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Test Type - Laboratory Testing and Point-of-Care Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Italy Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Test Type - Laboratory Testing and Point-of-Care Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 136: Italy 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Test Type - Percentage Breakdown of Value Sales for Laboratory Testing and Point-of-Care Testing for the Years 2015, 2025 & 2030
  • TABLE 137: Italy Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Technology - Polymerase Chain Reaction Technology, Isothermal Nucleic Acid Amplification Technology, Immunodiagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Italy Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Technology - Polymerase Chain Reaction Technology, Isothermal Nucleic Acid Amplification Technology, Immunodiagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 139: Italy 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction Technology, Isothermal Nucleic Acid Amplification Technology, Immunodiagnostics Technology and Other Technologies for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 140: UK Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Product Type - CT / NG Testing Consumables and CT / NG Testing Instruments / Analyzers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 141: UK Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Product Type - CT / NG Testing Consumables and CT / NG Testing Instruments / Analyzers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 142: UK 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Product Type - Percentage Breakdown of Value Sales for CT / NG Testing Consumables and CT / NG Testing Instruments / Analyzers for the Years 2015, 2025 & 2030
  • TABLE 143: UK Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by End-Use - Diagnostic Laboratories End-Use, Home Care Settings End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 144: UK Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by End-Use - Diagnostic Laboratories End-Use, Home Care Settings End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 145: UK 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Home Care Settings End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2015, 2025 & 2030
  • TABLE 146: UK Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Test Type - Laboratory Testing and Point-of-Care Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 147: UK Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Test Type - Laboratory Testing and Point-of-Care Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 148: UK 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Test Type - Percentage Breakdown of Value Sales for Laboratory Testing and Point-of-Care Testing for the Years 2015, 2025 & 2030
  • TABLE 149: UK Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Technology - Polymerase Chain Reaction Technology, Isothermal Nucleic Acid Amplification Technology, Immunodiagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 150: UK Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Technology - Polymerase Chain Reaction Technology, Isothermal Nucleic Acid Amplification Technology, Immunodiagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 151: UK 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction Technology, Isothermal Nucleic Acid Amplification Technology, Immunodiagnostics Technology and Other Technologies for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 152: Spain Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Product Type - CT / NG Testing Consumables and CT / NG Testing Instruments / Analyzers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Spain Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Product Type - CT / NG Testing Consumables and CT / NG Testing Instruments / Analyzers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 154: Spain 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Product Type - Percentage Breakdown of Value Sales for CT / NG Testing Consumables and CT / NG Testing Instruments / Analyzers for the Years 2015, 2025 & 2030
  • TABLE 155: Spain Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by End-Use - Diagnostic Laboratories End-Use, Home Care Settings End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Spain Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by End-Use - Diagnostic Laboratories End-Use, Home Care Settings End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 157: Spain 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Home Care Settings End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2015, 2025 & 2030
  • TABLE 158: Spain Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Test Type - Laboratory Testing and Point-of-Care Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Spain Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Test Type - Laboratory Testing and Point-of-Care Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 160: Spain 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Test Type - Percentage Breakdown of Value Sales for Laboratory Testing and Point-of-Care Testing for the Years 2015, 2025 & 2030
  • TABLE 161: Spain Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Technology - Polymerase Chain Reaction Technology, Isothermal Nucleic Acid Amplification Technology, Immunodiagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Spain Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Technology - Polymerase Chain Reaction Technology, Isothermal Nucleic Acid Amplification Technology, Immunodiagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 163: Spain 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction Technology, Isothermal Nucleic Acid Amplification Technology, Immunodiagnostics Technology and Other Technologies for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 164: Russia Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Product Type - CT / NG Testing Consumables and CT / NG Testing Instruments / Analyzers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Russia Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Product Type - CT / NG Testing Consumables and CT / NG Testing Instruments / Analyzers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 166: Russia 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Product Type - Percentage Breakdown of Value Sales for CT / NG Testing Consumables and CT / NG Testing Instruments / Analyzers for the Years 2015, 2025 & 2030
  • TABLE 167: Russia Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by End-Use - Diagnostic Laboratories End-Use, Home Care Settings End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Russia Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by End-Use - Diagnostic Laboratories End-Use, Home Care Settings End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 169: Russia 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Home Care Settings End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2015, 2025 & 2030
  • TABLE 170: Russia Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Test Type - Laboratory Testing and Point-of-Care Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Russia Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Test Type - Laboratory Testing and Point-of-Care Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 172: Russia 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Test Type - Percentage Breakdown of Value Sales for Laboratory Testing and Point-of-Care Testing for the Years 2015, 2025 & 2030
  • TABLE 173: Russia Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Technology - Polymerase Chain Reaction Technology, Isothermal Nucleic Acid Amplification Technology, Immunodiagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Russia Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Technology - Polymerase Chain Reaction Technology, Isothermal Nucleic Acid Amplification Technology, Immunodiagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 175: Russia 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction Technology, Isothermal Nucleic Acid Amplification Technology, Immunodiagnostics Technology and Other Technologies for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 176: Rest of Europe Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Product Type - CT / NG Testing Consumables and CT / NG Testing Instruments / Analyzers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Rest of Europe Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Product Type - CT / NG Testing Consumables and CT / NG Testing Instruments / Analyzers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 178: Rest of Europe 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Product Type - Percentage Breakdown of Value Sales for CT / NG Testing Consumables and CT / NG Testing Instruments / Analyzers for the Years 2015, 2025 & 2030
  • TABLE 179: Rest of Europe Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by End-Use - Diagnostic Laboratories End-Use, Home Care Settings End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Rest of Europe Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by End-Use - Diagnostic Laboratories End-Use, Home Care Settings End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 181: Rest of Europe 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Home Care Settings End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2015, 2025 & 2030
  • TABLE 182: Rest of Europe Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Test Type - Laboratory Testing and Point-of-Care Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Rest of Europe Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Test Type - Laboratory Testing and Point-of-Care Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 184: Rest of Europe 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Test Type - Percentage Breakdown of Value Sales for Laboratory Testing and Point-of-Care Testing for the Years 2015, 2025 & 2030
  • TABLE 185: Rest of Europe Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Technology - Polymerase Chain Reaction Technology, Isothermal Nucleic Acid Amplification Technology, Immunodiagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Rest of Europe Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Technology - Polymerase Chain Reaction Technology, Isothermal Nucleic Acid Amplification Technology, Immunodiagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 187: Rest of Europe 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction Technology, Isothermal Nucleic Acid Amplification Technology, Immunodiagnostics Technology and Other Technologies for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 188: Asia-Pacific Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 189: Asia-Pacific Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 190: Asia-Pacific 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 191: Asia-Pacific Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Product Type - CT / NG Testing Consumables and CT / NG Testing Instruments / Analyzers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Asia-Pacific Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Product Type - CT / NG Testing Consumables and CT / NG Testing Instruments / Analyzers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 193: Asia-Pacific 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Product Type - Percentage Breakdown of Value Sales for CT / NG Testing Consumables and CT / NG Testing Instruments / Analyzers for the Years 2015, 2025 & 2030
  • TABLE 194: Asia-Pacific Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by End-Use - Diagnostic Laboratories End-Use, Home Care Settings End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Asia-Pacific Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by End-Use - Diagnostic Laboratories End-Use, Home Care Settings End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 196: Asia-Pacific 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Home Care Settings End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2015, 2025 & 2030
  • TABLE 197: Asia-Pacific Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Test Type - Laboratory Testing and Point-of-Care Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Asia-Pacific Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Test Type - Laboratory Testing and Point-of-Care Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 199: Asia-Pacific 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Test Type - Percentage Breakdown of Value Sales for Laboratory Testing and Point-of-Care Testing for the Years 2015, 2025 & 2030
  • TABLE 200: Asia-Pacific Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Technology - Polymerase Chain Reaction Technology, Isothermal Nucleic Acid Amplification Technology, Immunodiagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Asia-Pacific Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Technology - Polymerase Chain Reaction Technology, Isothermal Nucleic Acid Amplification Technology, Immunodiagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 202: Asia-Pacific 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction Technology, Isothermal Nucleic Acid Amplification Technology, Immunodiagnostics Technology and Other Technologies for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 203: Australia Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Product Type - CT / NG Testing Consumables and CT / NG Testing Instruments / Analyzers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Australia Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Product Type - CT / NG Testing Consumables and CT / NG Testing Instruments / Analyzers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 205: Australia 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Product Type - Percentage Breakdown of Value Sales for CT / NG Testing Consumables and CT / NG Testing Instruments / Analyzers for the Years 2015, 2025 & 2030
  • TABLE 206: Australia Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by End-Use - Diagnostic Laboratories End-Use, Home Care Settings End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Australia Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by End-Use - Diagnostic Laboratories End-Use, Home Care Settings End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 208: Australia 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Home Care Settings End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2015, 2025 & 2030
  • TABLE 209: Australia Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Test Type - Laboratory Testing and Point-of-Care Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Australia Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Test Type - Laboratory Testing and Point-of-Care Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 211: Australia 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Test Type - Percentage Breakdown of Value Sales for Laboratory Testing and Point-of-Care Testing for the Years 2015, 2025 & 2030
  • TABLE 212: Australia Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Technology - Polymerase Chain Reaction Technology, Isothermal Nucleic Acid Amplification Technology, Immunodiagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Australia Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Technology - Polymerase Chain Reaction Technology, Isothermal Nucleic Acid Amplification Technology, Immunodiagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 214: Australia 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction Technology, Isothermal Nucleic Acid Amplification Technology, Immunodiagnostics Technology and Other Technologies for the Years 2015, 2025 & 2030
• INDIA
  • Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 215: India Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Product Type - CT / NG Testing Consumables and CT / NG Testing Instruments / Analyzers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 216: India Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Product Type - CT / NG Testing Consumables and CT / NG Testing Instruments / Analyzers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 217: India 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Product Type - Percentage Breakdown of Value Sales for CT / NG Testing Consumables and CT / NG Testing Instruments / Analyzers for the Years 2015, 2025 & 2030
  • TABLE 218: India Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by End-Use - Diagnostic Laboratories End-Use, Home Care Settings End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 219: India Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by End-Use - Diagnostic Laboratories End-Use, Home Care Settings End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 220: India 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Home Care Settings End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2015, 2025 & 2030
  • TABLE 221: India Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Test Type - Laboratory Testing and Point-of-Care Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 222: India Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Test Type - Laboratory Testing and Point-of-Care Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 223: India 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Test Type - Percentage Breakdown of Value Sales for Laboratory Testing and Point-of-Care Testing for the Years 2015, 2025 & 2030
  • TABLE 224: India Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Technology - Polymerase Chain Reaction Technology, Isothermal Nucleic Acid Amplification Technology, Immunodiagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 225: India Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Technology - Polymerase Chain Reaction Technology, Isothermal Nucleic Acid Amplification Technology, Immunodiagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 226: India 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction Technology, Isothermal Nucleic Acid Amplification Technology, Immunodiagnostics Technology and Other Technologies for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 227: South Korea Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Product Type - CT / NG Testing Consumables and CT / NG Testing Instruments / Analyzers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 228: South Korea Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Product Type - CT / NG Testing Consumables and CT / NG Testing Instruments / Analyzers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 229: South Korea 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Product Type - Percentage Breakdown of Value Sales for CT / NG Testing Consumables and CT / NG Testing Instruments / Analyzers for the Years 2015, 2025 & 2030
  • TABLE 230: South Korea Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by End-Use - Diagnostic Laboratories End-Use, Home Care Settings End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 231: South Korea Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by End-Use - Diagnostic Laboratories End-Use, Home Care Settings End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 232: South Korea 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Home Care Settings End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2015, 2025 & 2030
  • TABLE 233: South Korea Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Test Type - Laboratory Testing and Point-of-Care Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 234: South Korea Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Test Type - Laboratory Testing and Point-of-Care Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 235: South Korea 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Test Type - Percentage Breakdown of Value Sales for Laboratory Testing and Point-of-Care Testing for the Years 2015, 2025 & 2030
  • TABLE 236: South Korea Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Technology - Polymerase Chain Reaction Technology, Isothermal Nucleic Acid Amplification Technology, Immunodiagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 237: South Korea Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Technology - Polymerase Chain Reaction Technology, Isothermal Nucleic Acid Amplification Technology, Immunodiagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 238: South Korea 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction Technology, Isothermal Nucleic Acid Amplification Technology, Immunodiagnostics Technology and Other Technologies for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 239: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Product Type - CT / NG Testing Consumables and CT / NG Testing Instruments / Analyzers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Rest of Asia-Pacific Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Product Type - CT / NG Testing Consumables and CT / NG Testing Instruments / Analyzers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 241: Rest of Asia-Pacific 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Product Type - Percentage Breakdown of Value Sales for CT / NG Testing Consumables and CT / NG Testing Instruments / Analyzers for the Years 2015, 2025 & 2030
  • TABLE 242: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by End-Use - Diagnostic Laboratories End-Use, Home Care Settings End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Rest of Asia-Pacific Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by End-Use - Diagnostic Laboratories End-Use, Home Care Settings End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 244: Rest of Asia-Pacific 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Home Care Settings End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2015, 2025 & 2030
  • TABLE 245: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Test Type - Laboratory Testing and Point-of-Care Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Rest of Asia-Pacific Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Test Type - Laboratory Testing and Point-of-Care Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 247: Rest of Asia-Pacific 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Test Type - Percentage Breakdown of Value Sales for Laboratory Testing and Point-of-Care Testing for the Years 2015, 2025 & 2030
  • TABLE 248: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Technology - Polymerase Chain Reaction Technology, Isothermal Nucleic Acid Amplification Technology, Immunodiagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Rest of Asia-Pacific Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Technology - Polymerase Chain Reaction Technology, Isothermal Nucleic Acid Amplification Technology, Immunodiagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 250: Rest of Asia-Pacific 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction Technology, Isothermal Nucleic Acid Amplification Technology, Immunodiagnostics Technology and Other Technologies for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 251: Latin America Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 252: Latin America Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 253: Latin America 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 254: Latin America Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Product Type - CT / NG Testing Consumables and CT / NG Testing Instruments / Analyzers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Latin America Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Product Type - CT / NG Testing Consumables and CT / NG Testing Instruments / Analyzers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 256: Latin America 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Product Type - Percentage Breakdown of Value Sales for CT / NG Testing Consumables and CT / NG Testing Instruments / Analyzers for the Years 2015, 2025 & 2030
  • TABLE 257: Latin America Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by End-Use - Diagnostic Laboratories End-Use, Home Care Settings End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Latin America Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by End-Use - Diagnostic Laboratories End-Use, Home Care Settings End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 259: Latin America 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Home Care Settings End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2015, 2025 & 2030
  • TABLE 260: Latin America Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Test Type - Laboratory Testing and Point-of-Care Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Latin America Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Test Type - Laboratory Testing and Point-of-Care Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 262: Latin America 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Test Type - Percentage Breakdown of Value Sales for Laboratory Testing and Point-of-Care Testing for the Years 2015, 2025 & 2030
  • TABLE 263: Latin America Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Technology - Polymerase Chain Reaction Technology, Isothermal Nucleic Acid Amplification Technology, Immunodiagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Latin America Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Technology - Polymerase Chain Reaction Technology, Isothermal Nucleic Acid Amplification Technology, Immunodiagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 265: Latin America 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction Technology, Isothermal Nucleic Acid Amplification Technology, Immunodiagnostics Technology and Other Technologies for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 266: Argentina Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Product Type - CT / NG Testing Consumables and CT / NG Testing Instruments / Analyzers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Argentina Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Product Type - CT / NG Testing Consumables and CT / NG Testing Instruments / Analyzers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 268: Argentina 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Product Type - Percentage Breakdown of Value Sales for CT / NG Testing Consumables and CT / NG Testing Instruments / Analyzers for the Years 2015, 2025 & 2030
  • TABLE 269: Argentina Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by End-Use - Diagnostic Laboratories End-Use, Home Care Settings End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Argentina Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by End-Use - Diagnostic Laboratories End-Use, Home Care Settings End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 271: Argentina 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Home Care Settings End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2015, 2025 & 2030
  • TABLE 272: Argentina Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Test Type - Laboratory Testing and Point-of-Care Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Argentina Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Test Type - Laboratory Testing and Point-of-Care Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 274: Argentina 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Test Type - Percentage Breakdown of Value Sales for Laboratory Testing and Point-of-Care Testing for the Years 2015, 2025 & 2030
  • TABLE 275: Argentina Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Technology - Polymerase Chain Reaction Technology, Isothermal Nucleic Acid Amplification Technology, Immunodiagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Argentina Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Technology - Polymerase Chain Reaction Technology, Isothermal Nucleic Acid Amplification Technology, Immunodiagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 277: Argentina 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction Technology, Isothermal Nucleic Acid Amplification Technology, Immunodiagnostics Technology and Other Technologies for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 278: Brazil Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Product Type - CT / NG Testing Consumables and CT / NG Testing Instruments / Analyzers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Brazil Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Product Type - CT / NG Testing Consumables and CT / NG Testing Instruments / Analyzers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 280: Brazil 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Product Type - Percentage Breakdown of Value Sales for CT / NG Testing Consumables and CT / NG Testing Instruments / Analyzers for the Years 2015, 2025 & 2030
  • TABLE 281: Brazil Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by End-Use - Diagnostic Laboratories End-Use, Home Care Settings End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Brazil Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by End-Use - Diagnostic Laboratories End-Use, Home Care Settings End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 283: Brazil 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Home Care Settings End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2015, 2025 & 2030
  • TABLE 284: Brazil Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Test Type - Laboratory Testing and Point-of-Care Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Brazil Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Test Type - Laboratory Testing and Point-of-Care Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 286: Brazil 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Test Type - Percentage Breakdown of Value Sales for Laboratory Testing and Point-of-Care Testing for the Years 2015, 2025 & 2030
  • TABLE 287: Brazil Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Technology - Polymerase Chain Reaction Technology, Isothermal Nucleic Acid Amplification Technology, Immunodiagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Brazil Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Technology - Polymerase Chain Reaction Technology, Isothermal Nucleic Acid Amplification Technology, Immunodiagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 289: Brazil 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction Technology, Isothermal Nucleic Acid Amplification Technology, Immunodiagnostics Technology and Other Technologies for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 290: Mexico Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Product Type - CT / NG Testing Consumables and CT / NG Testing Instruments / Analyzers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Mexico Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Product Type - CT / NG Testing Consumables and CT / NG Testing Instruments / Analyzers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 292: Mexico 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Product Type - Percentage Breakdown of Value Sales for CT / NG Testing Consumables and CT / NG Testing Instruments / Analyzers for the Years 2015, 2025 & 2030
  • TABLE 293: Mexico Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by End-Use - Diagnostic Laboratories End-Use, Home Care Settings End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Mexico Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by End-Use - Diagnostic Laboratories End-Use, Home Care Settings End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 295: Mexico 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Home Care Settings End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2015, 2025 & 2030
  • TABLE 296: Mexico Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Test Type - Laboratory Testing and Point-of-Care Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Mexico Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Test Type - Laboratory Testing and Point-of-Care Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 298: Mexico 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Test Type - Percentage Breakdown of Value Sales for Laboratory Testing and Point-of-Care Testing for the Years 2015, 2025 & 2030
  • TABLE 299: Mexico Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Technology - Polymerase Chain Reaction Technology, Isothermal Nucleic Acid Amplification Technology, Immunodiagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Mexico Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Technology - Polymerase Chain Reaction Technology, Isothermal Nucleic Acid Amplification Technology, Immunodiagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 301: Mexico 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction Technology, Isothermal Nucleic Acid Amplification Technology, Immunodiagnostics Technology and Other Technologies for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 302: Rest of Latin America Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Product Type - CT / NG Testing Consumables and CT / NG Testing Instruments / Analyzers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Rest of Latin America Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Product Type - CT / NG Testing Consumables and CT / NG Testing Instruments / Analyzers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 304: Rest of Latin America 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Product Type - Percentage Breakdown of Value Sales for CT / NG Testing Consumables and CT / NG Testing Instruments / Analyzers for the Years 2015, 2025 & 2030
  • TABLE 305: Rest of Latin America Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by End-Use - Diagnostic Laboratories End-Use, Home Care Settings End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Rest of Latin America Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by End-Use - Diagnostic Laboratories End-Use, Home Care Settings End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 307: Rest of Latin America 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Home Care Settings End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2015, 2025 & 2030
  • TABLE 308: Rest of Latin America Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Test Type - Laboratory Testing and Point-of-Care Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Rest of Latin America Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Test Type - Laboratory Testing and Point-of-Care Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 310: Rest of Latin America 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Test Type - Percentage Breakdown of Value Sales for Laboratory Testing and Point-of-Care Testing for the Years 2015, 2025 & 2030
  • TABLE 311: Rest of Latin America Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Technology - Polymerase Chain Reaction Technology, Isothermal Nucleic Acid Amplification Technology, Immunodiagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Rest of Latin America Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Technology - Polymerase Chain Reaction Technology, Isothermal Nucleic Acid Amplification Technology, Immunodiagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 313: Rest of Latin America 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction Technology, Isothermal Nucleic Acid Amplification Technology, Immunodiagnostics Technology and Other Technologies for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 314: Middle East Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 315: Middle East Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 316: Middle East 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 317: Middle East Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Product Type - CT / NG Testing Consumables and CT / NG Testing Instruments / Analyzers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 318: Middle East Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Product Type - CT / NG Testing Consumables and CT / NG Testing Instruments / Analyzers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 319: Middle East 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Product Type - Percentage Breakdown of Value Sales for CT / NG Testing Consumables and CT / NG Testing Instruments / Analyzers for the Years 2015, 2025 & 2030
  • TABLE 320: Middle East Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by End-Use - Diagnostic Laboratories End-Use, Home Care Settings End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 321: Middle East Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by End-Use - Diagnostic Laboratories End-Use, Home Care Settings End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 322: Middle East 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Home Care Settings End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2015, 2025 & 2030
  • TABLE 323: Middle East Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Test Type - Laboratory Testing and Point-of-Care Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 324: Middle East Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Test Type - Laboratory Testing and Point-of-Care Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 325: Middle East 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Test Type - Percentage Breakdown of Value Sales for Laboratory Testing and Point-of-Care Testing for the Years 2015, 2025 & 2030
  • TABLE 326: Middle East Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Technology - Polymerase Chain Reaction Technology, Isothermal Nucleic Acid Amplification Technology, Immunodiagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 327: Middle East Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Technology - Polymerase Chain Reaction Technology, Isothermal Nucleic Acid Amplification Technology, Immunodiagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 328: Middle East 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction Technology, Isothermal Nucleic Acid Amplification Technology, Immunodiagnostics Technology and Other Technologies for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 329: Iran Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Product Type - CT / NG Testing Consumables and CT / NG Testing Instruments / Analyzers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 330: Iran Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Product Type - CT / NG Testing Consumables and CT / NG Testing Instruments / Analyzers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 331: Iran 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Product Type - Percentage Breakdown of Value Sales for CT / NG Testing Consumables and CT / NG Testing Instruments / Analyzers for the Years 2015, 2025 & 2030
  • TABLE 332: Iran Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by End-Use - Diagnostic Laboratories End-Use, Home Care Settings End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 333: Iran Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by End-Use - Diagnostic Laboratories End-Use, Home Care Settings End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 334: Iran 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Home Care Settings End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2015, 2025 & 2030
  • TABLE 335: Iran Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Test Type - Laboratory Testing and Point-of-Care Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 336: Iran Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Test Type - Laboratory Testing and Point-of-Care Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 337: Iran 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Test Type - Percentage Breakdown of Value Sales for Laboratory Testing and Point-of-Care Testing for the Years 2015, 2025 & 2030
  • TABLE 338: Iran Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Technology - Polymerase Chain Reaction Technology, Isothermal Nucleic Acid Amplification Technology, Immunodiagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 339: Iran Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Technology - Polymerase Chain Reaction Technology, Isothermal Nucleic Acid Amplification Technology, Immunodiagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 340: Iran 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction Technology, Isothermal Nucleic Acid Amplification Technology, Immunodiagnostics Technology and Other Technologies for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 341: Israel Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Product Type - CT / NG Testing Consumables and CT / NG Testing Instruments / Analyzers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 342: Israel Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Product Type - CT / NG Testing Consumables and CT / NG Testing Instruments / Analyzers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 343: Israel 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Product Type - Percentage Breakdown of Value Sales for CT / NG Testing Consumables and CT / NG Testing Instruments / Analyzers for the Years 2015, 2025 & 2030
  • TABLE 344: Israel Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by End-Use - Diagnostic Laboratories End-Use, Home Care Settings End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 345: Israel Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by End-Use - Diagnostic Laboratories End-Use, Home Care Settings End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 346: Israel 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Home Care Settings End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2015, 2025 & 2030
  • TABLE 347: Israel Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Test Type - Laboratory Testing and Point-of-Care Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 348: Israel Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Test Type - Laboratory Testing and Point-of-Care Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 349: Israel 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Test Type - Percentage Breakdown of Value Sales for Laboratory Testing and Point-of-Care Testing for the Years 2015, 2025 & 2030
  • TABLE 350: Israel Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Technology - Polymerase Chain Reaction Technology, Isothermal Nucleic Acid Amplification Technology, Immunodiagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 351: Israel Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Technology - Polymerase Chain Reaction Technology, Isothermal Nucleic Acid Amplification Technology, Immunodiagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 352: Israel 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction Technology, Isothermal Nucleic Acid Amplification Technology, Immunodiagnostics Technology and Other Technologies for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 353: Saudi Arabia Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Product Type - CT / NG Testing Consumables and CT / NG Testing Instruments / Analyzers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 354: Saudi Arabia Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Product Type - CT / NG Testing Consumables and CT / NG Testing Instruments / Analyzers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 355: Saudi Arabia 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Product Type - Percentage Breakdown of Value Sales for CT / NG Testing Consumables and CT / NG Testing Instruments / Analyzers for the Years 2015, 2025 & 2030
  • TABLE 356: Saudi Arabia Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by End-Use - Diagnostic Laboratories End-Use, Home Care Settings End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 357: Saudi Arabia Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by End-Use - Diagnostic Laboratories End-Use, Home Care Settings End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 358: Saudi Arabia 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Home Care Settings End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2015, 2025 & 2030
  • TABLE 359: Saudi Arabia Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Test Type - Laboratory Testing and Point-of-Care Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 360: Saudi Arabia Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Test Type - Laboratory Testing and Point-of-Care Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 361: Saudi Arabia 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Test Type - Percentage Breakdown of Value Sales for Laboratory Testing and Point-of-Care Testing for the Years 2015, 2025 & 2030
  • TABLE 362: Saudi Arabia Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Technology - Polymerase Chain Reaction Technology, Isothermal Nucleic Acid Amplification Technology, Immunodiagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 363: Saudi Arabia Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Technology - Polymerase Chain Reaction Technology, Isothermal Nucleic Acid Amplification Technology, Immunodiagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 364: Saudi Arabia 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction Technology, Isothermal Nucleic Acid Amplification Technology, Immunodiagnostics Technology and Other Technologies for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 365: UAE Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Product Type - CT / NG Testing Consumables and CT / NG Testing Instruments / Analyzers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 366: UAE Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Product Type - CT / NG Testing Consumables and CT / NG Testing Instruments / Analyzers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 367: UAE 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Product Type - Percentage Breakdown of Value Sales for CT / NG Testing Consumables and CT / NG Testing Instruments / Analyzers for the Years 2015, 2025 & 2030
  • TABLE 368: UAE Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by End-Use - Diagnostic Laboratories End-Use, Home Care Settings End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 369: UAE Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by End-Use - Diagnostic Laboratories End-Use, Home Care Settings End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 370: UAE 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Home Care Settings End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2015, 2025 & 2030
  • TABLE 371: UAE Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Test Type - Laboratory Testing and Point-of-Care Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 372: UAE Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Test Type - Laboratory Testing and Point-of-Care Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 373: UAE 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Test Type - Percentage Breakdown of Value Sales for Laboratory Testing and Point-of-Care Testing for the Years 2015, 2025 & 2030
  • TABLE 374: UAE Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Technology - Polymerase Chain Reaction Technology, Isothermal Nucleic Acid Amplification Technology, Immunodiagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 375: UAE Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Technology - Polymerase Chain Reaction Technology, Isothermal Nucleic Acid Amplification Technology, Immunodiagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 376: UAE 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction Technology, Isothermal Nucleic Acid Amplification Technology, Immunodiagnostics Technology and Other Technologies for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 377: Rest of Middle East Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Product Type - CT / NG Testing Consumables and CT / NG Testing Instruments / Analyzers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 378: Rest of Middle East Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Product Type - CT / NG Testing Consumables and CT / NG Testing Instruments / Analyzers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 379: Rest of Middle East 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Product Type - Percentage Breakdown of Value Sales for CT / NG Testing Consumables and CT / NG Testing Instruments / Analyzers for the Years 2015, 2025 & 2030
  • TABLE 380: Rest of Middle East Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by End-Use - Diagnostic Laboratories End-Use, Home Care Settings End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 381: Rest of Middle East Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by End-Use - Diagnostic Laboratories End-Use, Home Care Settings End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 382: Rest of Middle East 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Home Care Settings End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2015, 2025 & 2030
  • TABLE 383: Rest of Middle East Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Test Type - Laboratory Testing and Point-of-Care Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 384: Rest of Middle East Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Test Type - Laboratory Testing and Point-of-Care Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 385: Rest of Middle East 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Test Type - Percentage Breakdown of Value Sales for Laboratory Testing and Point-of-Care Testing for the Years 2015, 2025 & 2030
  • TABLE 386: Rest of Middle East Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Technology - Polymerase Chain Reaction Technology, Isothermal Nucleic Acid Amplification Technology, Immunodiagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 387: Rest of Middle East Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Technology - Polymerase Chain Reaction Technology, Isothermal Nucleic Acid Amplification Technology, Immunodiagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 388: Rest of Middle East 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction Technology, Isothermal Nucleic Acid Amplification Technology, Immunodiagnostics Technology and Other Technologies for the Years 2015, 2025 & 2030
• AFRICA
  • Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 389: Africa Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Product Type - CT / NG Testing Consumables and CT / NG Testing Instruments / Analyzers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 390: Africa Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Product Type - CT / NG Testing Consumables and CT / NG Testing Instruments / Analyzers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 391: Africa 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Product Type - Percentage Breakdown of Value Sales for CT / NG Testing Consumables and CT / NG Testing Instruments / Analyzers for the Years 2015, 2025 & 2030
  • TABLE 392: Africa Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by End-Use - Diagnostic Laboratories End-Use, Home Care Settings End-Use, Other End-Uses and Hospitals & Clinics End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 393: Africa Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by End-Use - Diagnostic Laboratories End-Use, Home Care Settings End-Use, Other End-Uses and Hospitals & Clinics End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 394: Africa 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Home Care Settings End-Use, Other End-Uses and Hospitals & Clinics End-Use for the Years 2015, 2025 & 2030
  • TABLE 395: Africa Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Test Type - Laboratory Testing and Point-of-Care Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 396: Africa Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Test Type - Laboratory Testing and Point-of-Care Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 397: Africa 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Test Type - Percentage Breakdown of Value Sales for Laboratory Testing and Point-of-Care Testing for the Years 2015, 2025 & 2030
  • TABLE 398: Africa Recent Past, Current & Future Analysis for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Technology - Polymerase Chain Reaction Technology, Isothermal Nucleic Acid Amplification Technology, Immunodiagnostics Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 399: Africa Historic Review for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Technology - Polymerase Chain Reaction Technology, Isothermal Nucleic Acid Amplification Technology, Immunodiagnostics Technology and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 400: Africa 15-Year Perspective for Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG) Testing by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction Technology, Isothermal Nucleic Acid Amplification Technology, Immunodiagnostics Technology and Other Technologies for the Years 2015, 2025 & 2030

IV. COMPETITION